生物主动脉瓣叶片钙化与血流动力学及临床结局的关联
本研究前瞻性纳入204例生物主动脉瓣置换术后患者,中位随访7.0年,用CT测瓣叶钙化密度(AVCd),分析其与血流动力学瓣膜恶化(HVD)及死亡/再干预的关联。结果显示AVCd≥58 AU/cm²独立增加死亡或再干预风险(aHR 2.23),且无性别差异。
要点
- 生物瓣叶钙化密度(AVCd)≥58 AU/cm²独立预测死亡或主动脉瓣再干预。
- AVCd与3年HVD独立相关,联合平均压差进展≥10 mmHg可增强风险分层。
- 与原生主动脉瓣狭窄不同,AVCd与结局的关系无性别差异。
核心结论
- 生物主动脉瓣叶片钙化与HVD及死亡或再干预风险独立强相关。
- AVCd与血流动力学或临床结局的关系无性别差异。
研究设计与样本
- 前瞻性队列研究,2008-2010年纳入204例生物主动脉瓣置换术后患者,中位随访7.0年(IQR 5.1-9.2年)。
- 用Agatston法测瓣叶钙化,以超声测瓣环横截面积标化得AVCd;137例患者在3年随访时评估HVD。
主要发现
- 基线AVCd与3年HVD独立相关。
- 随访期间134例(65.7%)发生死亡(n=100)或瓣膜再干预(n=47)。
- AVCd≥58 AU/cm²独立增加死亡或再干预风险(aHR 2.23,95%CI 1.44-3.35,p<0.001)。
- AVCd阈值联合平均压差进展≥10 mmHg增强风险分层(log-rank p<0.001)。
- 将AVCd阈值加入传统风险因素模型改善预测(NRI 0.25,p=0.04;似然比检验p<0.001)。
关键数值与推荐
- AVCd计算方法:Agatston法测钙化除以超声瓣环横截面积。
- HVD定义:平均压差增加≥10 mmHg和/或经瓣反流增加≥1级。
- AVCd阈值:≥58 AU/cm²独立预测死亡或再干预。
临床怎么用
- 生物主动脉瓣置换术后可用CT定量瓣叶钙化密度(AVCd)辅助风险分层。
- AVCd≥58 AU/cm²提示死亡或再干预风险增高,可考虑加强随访。
- 联合AVCd与平均压差进展可进一步识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic value of aortic valve calcification (AVC) measured by using multidetector computed tomography imaging has been well validated in native aortic stenosis, and sex-specific thresholds have been proposed. However, few data are available regarding the impact of leaflet calcification on outcomes after biological aortic valve replacement (AVR). OBJECTIVES: The goal of this study was to analyze the association of quantitative bioprosthetic leaflet AVC with hemodynamic and clinical outcomes, as well as its possible interaction with sex. METHODS: From 2008 to 2010, a total of 204 patients were prospectively enrolled with a median of 7.0 years (interquartile range: 5.1 to 9.2 years) after biological surgical AVR. AVC measured by using the Agatston method was indexed to the cross-sectional area of aortic annulus measured by echocardiography to calculate the AVC density (AVCd). Presence of hemodynamic valve deterioration (HVD; increase in mean gradient [MG] ≥10 mm Hg and/or increase in transprosthetic regurgitation ≥1) was assessed by echocardiography in 137 patients at the 3-year follow-up. The primary clinical endpoint was mortality or aortic valve re-intervention. RESULTS: There was no significant sex-related difference in the relationship between bioprosthetic AVCd and the progression of MG. Baseline AVCd showed an independent association with HVD at 3 years. During follow-up, there were 134 (65.7%) deaths (n = 100) or valve re-interventions (n = 47). AVCd ≥58 AU/cm2 was independently associated with an increased risk of mortality or aortic valve re-intervention (adjusted hazard ratio: 2.23; 95% confidence interval: 1.44 to 3.35; p < 0.001). The AVCd threshold combined with an MG progression threshold of 10 mm Hg amplified the stratification of patients at risk (log-rank, p < 0.001). The addition of AVCd threshold into the prediction model including traditional risk factors improved outcome prediction (net classification improvement: 0.25, p = 0.04; likelihood ratio test, p < 0.001). CONCLUSIONS: Aortic bioprosthetic leaflet calcification is strongly and independently associated with HVD and the risk of death or aortic valve re-intervention. As opposed to native aortic stenosis, there is no sex-related differences in the relationship between AVCd and hemodynamic or clinical outcomes.
引用
- Zhang B, Salaun E, Côté N, et al. Association of Bioprosthetic Aortic Valve Leaflet Calcification on Hemodynamic and Clinical Outcomes. J Am Coll Cardiol. 2020. PMID: 33032735. doi:10.1016/j.jacc.2020.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。